🇫🇷 IPN.PA — Ipsen S.A.

Salud Mantener
← Volver

Precio actual

155,80 EUR

Máx. histórico

172,90

182 días

Caída desde máximo

-9,89%

Rango 52 semanas

115,60 – 174,00

Variación hoy

+1,70%

Cierre anterior

153,20

Rango de hoy

153,30 – 155,90

Volumen hoy

107.342

Peor caída histórica

-75,62%

30/08/2018 → 18/03/2020

Recuperado en 2157 días

Volatilidad anualizada ⓘ

30,51%

Información
Nombre completo
Ipsen S.A.
Divisa
EUR
Mercado
Paris
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
5.535
PER ⓘ
25,21 (puede no estar actualizado)
Dividend yield
1,04% (puede no estar actualizado)
Precio objetivo analistas
161,92 EUR (puede no estar actualizado)
Primera cotización
07/12/2005
Precio actualizado
hace 17 horas
Sobre la empresa

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Dividendos repartidos Total últimos 12 meses: 1,6000 EUR · Yield: 1,03%
Fecha de pago Importe por participación
03/06/2026 1,6000 EUR
04/06/2025 1,4000 EUR
30/05/2024 1,2000 EUR
02/06/2023 1,2000 EUR
31/05/2022 1,2000 EUR
31/05/2021 1,0000 EUR
03/06/2020 1,0000 EUR
31/05/2019 1,0000 EUR
04/06/2018 1,0000 EUR
09/06/2017 0,8500 EUR
02/06/2016 0,8500 EUR
29/05/2015 0,8500 EUR
09/06/2014 0,8000 EUR
05/06/2013 0,8000 EUR
06/06/2012 0,8000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
06/03/2012 20,03 20,09 19,39 19,54 -2,45% 3,47% 146.454
05/03/2012 20,15 20,35 20,03 20,03 -0,60% 1,61% 133.564
02/03/2012 20,40 20,40 20,06 20,15 -0,52% 1,69% 145.592
01/03/2012 20,00 20,26 19,42 20,26 +0,30% 4,17% 320.331
29/02/2012 21,21 21,25 19,95 20,20 -8,62% 6,13% 599.618
28/02/2012 21,88 22,20 21,80 22,10 +0,91% 1,83% 68.520
27/02/2012 22,01 22,09 21,83 21,90 -0,86% 1,18% 100.464
24/02/2012 21,73 22,18 21,26 22,09 -3,54% 4,21% 193.761
23/02/2012 23,01 23,05 22,83 22,90 -0,87% 0,98% 103.300
22/02/2012 23,00 23,25 22,93 23,10 +0,11% 1,39% 69.124
21/02/2012 23,00 23,12 22,81 23,08 +0,50% 1,37% 47.741
20/02/2012 22,86 23,04 22,67 22,96 +0,50% 1,62% 60.834
17/02/2012 23,04 23,04 22,82 22,85 -0,54% 0,95% 120.001
16/02/2012 22,61 22,97 22,43 22,97 +1,41% 2,39% 73.477
15/02/2012 22,71 22,84 22,47 22,65 -0,09% 1,63% 62.132
14/02/2012 22,52 22,90 22,42 22,67 +0,40% 2,13% 92.291
13/02/2012 22,61 22,65 22,35 22,58 +0,38% 1,33% 34.694
10/02/2012 22,21 22,55 22,07 22,50 +0,96% 2,16% 137.338
09/02/2012 22,26 22,36 21,93 22,28 +0,09% 1,93% 176.854
08/02/2012 22,00 22,40 21,90 22,26 +1,16% 2,25% 93.787
07/02/2012 22,02 22,20 21,56 22,01 +0,00% 2,88% 162.499
06/02/2012 22,01 22,18 21,81 22,01 -0,18% 1,70% 119.014
03/02/2012 21,70 22,08 21,64 22,05 +1,59% 2,03% 119.075
02/02/2012 21,50 21,96 21,03 21,70 -5,65% 4,33% 324.081
01/02/2012 22,57 23,19 22,44 23,00 +2,43% 3,30% 97.337
31/01/2012 22,57 22,74 22,25 22,46 -0,31% 2,17% 106.595
30/01/2012 23,10 23,10 22,53 22,53 -2,72% 2,49% 76.118
27/01/2012 23,31 23,38 23,04 23,16 -0,66% 1,46% 123.940
26/01/2012 23,67 23,82 23,26 23,31 -1,48% 2,35% 55.494
25/01/2012 23,94 23,94 23,31 23,66 -0,21% 2,65% 27.159